A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 441 participants.
Also called NCT01191255
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 441 participants
- Sponsor
- Registry
-
NCT01191255
-
- Other papers using this trial's data
- Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Israel, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01191255. Randomized; no masking; primary purpose prevention. Start 2010-10 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-12-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
- Condition
- Hyperphosphatemia
- Condition
- Kidney Failure
- Intervention (Drug)
- ferric citrate, ca acetate, sevelamer carbonate, placebo
- Lead sponsor
- Keryx Biopharmaceuticals
Record details
- Record id
cardio:ct-nct01191255- Content hash
1abd589fefece1ea62be4cd97e000a50af828f47006ddda4fb31e08fa1d5e276